咨询客服 咨询客服

Baduanjin exerts anti-diabetic and anti-depression effects by regulating the expression of mRNA, lncRNA, and circRNA

Abstract:
BackgroundBaduanjin, a traditional Chinese exercise therapy, has been widely used in China to treat type 2 diabetes (T2DM) with depression (DD). However, the underlying mechanism of Baduanjin in anti-DD is unclear. This study was focused on investigating the effects of Baduanjin on symptoms of depression and blood glucose in patients with DD and the underlying mechanism.MethodsWe performed a 12-week Baduanjin intervention on patients with DD and longitudinally compared the differential expressions of lncRNAs, circRNAs, and mRNAs between pre- (BDD) and post- (ADD) Baduanjin intervention in the same group. Subsequently, Gene Ontology (GO) and pathway analysis was performed to investigate the function of differentially expressed mRNAs. Finally, Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was used to verify the sequencing result and the mRNA-lncRNA regulatory network was constructed.ResultsThe blood glucose level, depression index scores, and PHQ9 scores of the patients with DD were significantly decreased (P\u2009<\u20090.05) after Baduanjin intervention. Compared to BDD, 207 lncRNAs, 266 circRNAs, and 610 differentially expressed mRNAs were identified in ADD. Kyoto Encyclopedia of Genes and Genomes (KEGG) and GO showed that the significantly dysregulated mRNAs were mainly involved in immune function and inflammatory response pathways, and various signaling pathways including IL-17 and TNF. In addition, we selected five differentially expressed lncRNAs to construct an lncRNA-mRNA regulatory network, and found a total of 1045 mRNAs associated with them.ConclusionsOur research is the first systematic profiling of mRNA, lncRNA, and circRNA in patients of ADD and BDD, and provides valuable insights in the potential mechanism of Baduanjin in anti-DD. Further, it was confirmed that Baduanjin is a safe and effective intervention for patients with DD because it can effectively ameliorate the symptoms of depression and blood glucose levels in patients with DD by regulating the dysregulated expression of lncRNA, mRNA, and circRNA.
Author Listing: Tian An;Zhong-Chen He;Xin-Qing Zhang;Jun Li;Ai-Ling Chen;Fang Tan;Hong-Dong Chen;Bo-Han Lv;Juan Lian;Si-Hua Gao;Guang-Jian Jiang
Volume: 14
Pages: None
DOI: 10.1186/s13020-019-0225-1
Language: English
Journal: Chinese Medicine

Chinese Medicine

CHIN MED-UK

影响因子:5.3
是否综述期刊:否
是否OA:是
是否预警:不在预警名单内
发行时间:2006
ISSN:1749-8546
发刊频率:-
收录数据库:SCIE/Scopus收录/DOAJ开放期刊
出版国家/地区:ENGLAND
出版社:BioMed Central

期刊介绍

Chinese Medicine is an open access, online journal publishing evidence-based, scientifically justified, and ethical research into all aspects of Chinese medicine.Areas of interest include recent advances in herbal medicine, clinical nutrition, clinical diagnosis, acupuncture, pharmaceutics, biomedical sciences, epidemiology, education, informatics, sociology, and psychology that are relevant and significant to Chinese medicine. Examples of research approaches include biomedical experimentation, high-throughput technology, clinical trials, systematic reviews, meta-analysis, sampled surveys, simulation, data curation, statistics, omics, translational medicine, and integrative methodologies.Chinese Medicine is a credible channel to communicate unbiased scientific data, information, and knowledge in Chinese medicine among researchers, clinicians, academics, and students in Chinese medicine and other scientific disciplines of medicine.

《中国医学》是一本开放获取的在线期刊,以循证、科学和伦理为基础,对中医药的各个方面进行研究。感兴趣的领域包括与中医药相关和重要的草药、临床营养、临床诊断、针灸、药剂学、生物医学、流行病学、教育、信息学、社会学和心理学的最新进展。研究方法的例子包括生物医学实验、高通量技术、临床试验、系统综述、荟萃分析、抽样调查、模拟、数据管理、统计学、组学、转化医学和综合方法学。中医药是研究人员、临床医生、学者之间交流公正的中医药科学数据、信息和知识的可靠渠道。和其他医学科学学科的学生。

年发文量 157
国人发稿量 150
国人发文占比 95.54%
自引率 5.7%
平均录取率 -
平均审稿周期 31 Weeks
版面费 US$2890
偏重研究方向 INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY
期刊官网 https://www.springer.com/journal/13020
投稿链接 https://www.editorialmanager.com/CMED

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
73.25% 100.00% 0.00% 1.60%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q1区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
PHARMACOLOGY & PHARMACY Q1
INTEGRATIVE & COMPLEMENTARY MEDICINE Q1

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY
药学
3区
INTEGRATIVE & COMPLEMENTARY MEDICINE
全科医学与补充医学
2区
2021年12月
基础版
医学
3区
PHARMACOLOGY & PHARMACY
药学
3区
INTEGRATIVE & COMPLEMENTARY MEDICINE
全科医学与补充医学
2区
2021年12月
升级版
医学
3区
PHARMACOLOGY & PHARMACY
药学
3区
INTEGRATIVE & COMPLEMENTARY MEDICINE
全科医学与补充医学
2区
2020年12月
旧的升级版
医学
3区
PHARMACOLOGY & PHARMACY
药学
3区
INTEGRATIVE & COMPLEMENTARY MEDICINE
全科医学与补充医学
3区
2022年12月
最新升级版
医学
3区
PHARMACOLOGY & PHARMACY
药学
2区
INTEGRATIVE & COMPLEMENTARY MEDICINE
全科医学与补充医学
2区